Season’s greetings from PExA – advancing lung disease research and diagnostics together!
As we reflect on the past year and look ahead to new possibilities, we want to extend our heartfelt thanks to our valued customers, partners and stakeholders. Your continued support empowers our mission to transform lung disease research and diagnostics with pioneering non-invasive technology.
How PExA works:
PExA’s solution collects and analyzes microscopic particles from the small airways in exhaled air—a region of the lungs that has historically been difficult to access and sample. Since many lung diseases originate and develop in this area long before symptoms appear, PExA’s innovative, non-invasive approach helps researchers identify biomarkers, unlocking new possibilities for early detection, personalized diagnosis and improved treatment of lung diseases.
Aligned with Sweden’s cancer strategy
Sweden’s updated cancer strategy, Better Together, emphasizes reducing cancer risk, enabling earlier diagnoses and promoting person-centered care. It highlights the importance of equitable treatment and improving quality of life during and after cancer. The strategy also highlights a significant gap in research on cancer prevention and early diagnosis, calling for targeted investments in these crucial areas.
How PExA contributes:
PExA’s innovative technology supports lung cancer research and is already being applied in clinical studies. One such project, “Diagnosis in a Breath: Exhaled Breath Particles as a Non-Invasive Method for Diagnosing and Monitoring Patients with Non-Small-Cell Lung Cancer”, led by researchers at Lund University and partially funded by the Swedish Cancer Society, highlights its potential.
By enabling accessible, efficient and patient-centered research, PExA drives progress toward more equitable and proactive lung cancer diagnosis and care. Through the adoption of PExA’s pioneering technology, customers are leading advancements in addressing one of the world’s most urgent health challenges.
Why it matters:
- Global need: Lung cancer’s devastating impact demands cutting-edge solutions. PExA is uniquely equipped to meet this need.
- Breakthrough diagnostics: PExA’s method enables researchers to gain previously unattainable insights into the small airways, opening doors to earlier and more personalized respiratory disease diagnostics.
- Swedish innovation leadership: Born from research at Sahlgrenska Academy, PExA demonstrates how academic breakthroughs can transform global healthcare.
“With our non-invasive technology, we aim to revolutionize the early detection of lung cancer and other respiratory diseases, equipping researchers and clinicians with the tools and data to improve patient outcomes,” —Tomas Gustafsson, CEO, PExA.
Learn more: